Details for Patent: 10,172,802

Which drugs does patent 10,172,802 protect, and when does it expire?

Patent 10,172,802 protects ORTIKOS and is included in one NDA.

This patent has three patent family members in three countries.

Summary for Patent: 10,172,802

Title:	Oral pharmaceutical dosage forms of budesonide
Abstract:	The present invention relates to novel oral sustained release pharmaceutical dosage forms for delivery of budesonide to the lower gastrointestinal tract for the treatment of Crohn's disease.
Inventor(s):	Rajamannar Thennati, Shirish Kulkarni, Amol Kulkarni, Vimal Kaneria, Mukesh Sharma
Assignee:	Sun Pharmaceutical Industries Ltd
Application Number:	US15/626,426
Patent Claim Types: see list of patent claims	Use; Formulation; Delivery; Dosage form;

Drugs Protected by US Patent 10,172,802

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sun Pharm Inds Inc	ORTIKOS	budesonide	CAPSULE, DELAYED RELEASE;ORAL	211929-001	Jun 13, 2019		DISCN	Yes	No	10,172,802					TREATMENT OF MILD TO MODERATE ACTIVE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON
Sun Pharm Inds Inc	ORTIKOS	budesonide	CAPSULE, DELAYED RELEASE;ORAL	211929-002	Jun 13, 2019		DISCN	Yes	No	10,172,802					TREATMENT OF MILD TO MODERATE ACTIVE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON

Foreign Priority and PCT Information for Patent: 10,172,802

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
India	3498/MUM/2015	Sep 11, 2015

International Family Members for US Patent 10,172,802

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3346996
Japan	2018530535
World Intellectual Property Organization (WIPO)	2017042835